Connect with us

coronavirus

EU's marathon COVID vaccination drive off to uneven start

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The EU’s campaign to vaccinate Europeans against COVID-19 has got off to an uneven start in what will be a marathon effort to administer shots to enough of the bloc’s 450 million people to defeat the viral pandemic, write and

In one mishap, eight workers at a care home in Stralsund on the north German coast were injected with five times the recommended dose of the vaccine developed by Pfizer and BioNTech. Four were hospitalised.

“I deeply regret the incident. This individual case is due to individual errors. I hope that all those affected do not experience any serious side effects,” district chief Stefan Kerth said on Monday (28 December).

In southern Germany, officials had to send back about 1,000 doses after finding they had been transported in cool boxes typically used for picnics or camping trips that failed to keep the vaccine cold enough.

Advertisement

The EU vaccination drive kicked off at the weekend, with health workers and residents of care homes across the bloc among the first to get the shots from Pfizer, which must be stored at ultra-cold temperatures.

In Italy, meanwhile, some politicians complained that Germany - the EU’s largest member state and home to BioNTech - may be getting more than its fair share of shots.

The EU is due to receive its first 12.5 million doses of the Pfizer vaccine by New Year’s Day, with distribution of 200 million doses across its 27 member countries to be completed by next September. The vaccine course requires two doses.

Advertisement

A spokesman for Pfizer declined to comment on specific schedules or whether the timeline indicated by the Commission represented a delay. “Our timelines are aspirational and can shift based on capacity and manufacturing timelines,” he said.

Talks are under way to agree on the delivery of an optional further 100 million doses under the contract sealed with the two companies, the EU said.

German vaccination campaign overshadowed by mishaps

The initial glitches highlight the challenge in rolling out the vaccine while regulators consider approving other vaccines, including from Moderna and AstraZeneca, which are easier to transport and store.

The rollout of the Pfizer shot in the United States has been slow, putting the government’s target of 20 million vaccinations this month in doubt, as hospitals navigate preparing the previously frozen shots for use, finding staff to run clinics and ensuring proper social distancing.

As well as being the first COVID-19 vaccine to be delivered across the EU, the Pfizer shot is particularly tricky to handle. For long-term storage it needs to be deep frozen at about minus 70 Celsius (minus 94 Fahrenheit).

It can be defrosted for a few days before being used, but even then must be kept chilled at between 2C and 8C.

In southern Germany, officials said they would not use some shots after temperature trackers in cool boxes showed they may not have been kept cold enough.

“There were doubts as to whether the cold chain was maintained at all times,” said Christian Meissner, district administrator in the Bavarian town of Lichtenfels.

“BioNTech said that the vaccine was probably okay, but ‘probably okay’ is not enough,” he told Reuters TV.

The lapse happened after the doses were handed over to the local authorities. BioNTech declined to comment.

In Spain, delivery of a new batch from Pfizer was held up by a day to Tuesday due to a temperature issue that has now been resolved, Health Minister Salvador Illa said.

Maria Asuncion Ojeda, a resident at Madrid’s Ballesol Parque Almansa nursing home, was still delighted to be an early recipient of the Pfizer vaccine.

“I wanted to do it because it’s the only way we can solve this problem,” the 87-year-old said on Monday, a day after Spain began vaccinating care-home residents and their staff.

The EU is distributing jointly procured vaccines on a pro-rata basis to the 27 member states based on their populations, while some European countries have also made their own deals to buy extra doses separately.

In Italy, some politicians said Germany appeared to be getting more than its fair share, at least during the highly symbolic initial rollout.

“The accounts don’t add up,” Italian virologist Roberto Burioni said on Twitter, pointing to reports in Germany that first-day deliveries had totalled more than 150,000 doses while other EU countries got just 10,000.

An official familiar with vaccine distribution in Germany said that each of the 16 German federal states had received 10,000 doses of the Pfizer vaccine ahead of the weekend start of the inoculation drive.

An Italian reporter asked about the supplies at a German government news conference. An official from the German health ministry replied that Berlin had signed a separate deal for 30 million extra doses of the Pfizer vaccine.

coronavirus

US-EU agenda for beating the global pandemic: Vaccinating the world, saving lives now, and building back better health security

Published

on

Vaccination is the most effective response to the COVID pandemic. The United States and the EU are technological leaders in advanced vaccine platforms, given decades of investments in research and development.

It is vital that we aggressively pursue an agenda to vaccinate the world. Co-ordinated US and EU leadership will help expand supply, deliver in a more coordinated and efficient manner, and manage constraints to supply chains. This will showcase the force of a Transatlantic partnership in facilitating global vaccination while enabling more progress by multilateral and regional initiatives.

Building on the outcome of the May 2021 G20 Global Health Summit, the G7 and US-EU Summits in June, and on the upcoming G20 Summit, the US and the EU will expand cooperation for global action toward vaccinating the world, saving lives now, and building better health security.  

Advertisement

Pillar I: A Joint EU/US Vaccine Sharing Commitment: the United States and the EU will share doses globally to enhance vaccination rates, with a priority on sharing through COVAX and improving vaccination rates urgently in low and lower-middle income countries. The United States is donating over 1.1 billion doses, and the EU will donate over 500 million doses. This is in addition to the doses we have financed through COVAX.

We call for nations that are able to vaccinate their populations to double their dose-sharing commitments or to make meaningful contributions to vaccine readiness. They will place a premium on predictable and effective dose-sharing to maximize sustainability and minimize waste.

Pillar II: A Joint EU/US Commitment to Vaccine Readiness: the United States and the EU will both support and coordinate with relevant organisations for vaccine delivery, cold chain, logistics, and immunization programs to translate doses in vials into shots in arms. They will share lessons learned from dose sharing, including delivery via COVAX, and promote equitable distribution of vaccines.

Advertisement

Pillar III: A Joint EU/US partnership on bolstering global vaccine supply and therapeutics: the EU and the United States will leverage their newly launched Joint COVID-19 Manufacturing and Supply Chain Taskforce to support vaccine and therapeutic manufacturing and distribution and overcome supply chain challenges. Collaborative efforts, outlined below, will include monitoring global supply chains, assessing global demand against the supply of ingredients and production materials, and identifying and addressing in real time bottlenecks and other disruptive factors for global vaccine and therapeutics production, as well as coordinating potential solutions and initiatives to boost global production of vaccines, critical inputs, and ancillary supplies.

Pillar IV: A Joint EU/US Proposal to achieve Global Health Security. The United States and the EU will support the establishment of a Financial Intermediary Fund (FIF) by the end of 2021 and will support its sustainable capitalization.  The EU and United States will also support global pandemic surveillance, including the concept of a global pandemic radar. The EU and the United States, through HERA and the Department of Health and Human Services Biomedical Advanced Research and Development Authority, respectively, will cooperate in line with our G7 commitment to expedite the development of new vaccines and make recommendations on enhancing the world's capacity to deliver these vaccines in real time. 

We call on partners to join in establishing and financing the FIF to support to prepare countries for COVID-19 and future biological threats.

Pillar V: A Joint EU/US/Partners Roadmap for regional vaccine production. The EU and the United States will coordinate investments in regional manufacturing capacity with low and lower-middle income countries, as well as targeted efforts to enhance capacity for medical countermeasures under the Build Back and Better World infrastructure and the newly established Global Gateway partnership. The EU and the United States will align efforts to bolster local vaccine manufacturing capacity in Africa and forge ahead on discussions on expanding the production of COVID-19 vaccines and treatments and ensure their equitable access.

We call on partners to join in supporting coordinated investments to expand global and regional manufacturing, including for mRNA, viral vector, and/or protein subunit COVID-19 vaccines.

More information

Joint statement on the launch of the joint COVID-19 Manufacturing and Supply Chain Taskforce

Continue Reading

coronavirus

Coronavirus: 200th EU disinfection robot delivered to European hospital, a further 100 confirmed

Published

on

On 21 September, the Commission delivered the 200th disinfection robot – to Consorci Corporació Sanitària Parc Taulí hospital in Barcelona. The robots, donated by the Commission, help sanitize COVID-19 patient rooms and are part of the Commission's action to supply hospitals across the EU to help them cope with the effects of the coronavirus pandemic. Further to these initial 200 robots announced in November last year, the Commission secured the purchase an additional 100, bringing the total donations to 300.

A Europe fit for the Digital Age Executive Vice President for Margrethe Vestager, said: “Assisting member states overcome the challenges of the pandemic continues to be a number one priority and these donations – a very tangible form of support – are a prime example of what can be achieved. This is European solidarity in action and I am pleased to see the Commission can go the extra mile in donating an additional 100 disinfection robots to hospitals in need.”

Twenty-five disinfection robots have already been working night and day across Spain since February to help tackle the spread of the coronavirus. Nearly every EU Member State has now received at least one disinfection robot, which disinfects a standard patient room in under 15 minutes, alleviating hospital staff and offering them and their patients greater protection against potential infection. This action is made possible through the Emergency Support Instrument and the devices are supplied by Danish company UVD robots, which won an emergency procurement tender.

Advertisement

Continue Reading

coronavirus

Coronavirus: Commission signs contract for the supply of a monoclonal antibody treatment

Published

on

The Commission has signed a joint procurement framework contract with the pharmaceutical company Eli Lilly for the supply of a monoclonal antibody treatment for coronavirus patients. This marks the latest development in this first portfolio of five promising therapeutics announced by the Commission under the EU COVID-19 Therapeutics Strategy in June 2021. The medicine is currently under rolling review by the European Medicines Agency. 18 member states have signed up to the joint procurement for the purchase of up to 220,000 treatments.

Health and Food Safety Commissioner Stella Kyriakides said: “Over 73% of the EU adult population is now fully vaccinated, and this rate will still increase. But vaccines cannot be our only response to COVID-19. People still continue to be infected and fall ill. We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics. With today's signature, we conclude our third procurement and deliver on our commitment under the EU Therapeutics Strategy to facilitate access to state-of-the-art medicines for COVID-19 patients.”

While vaccination remains the strongest asset both against the virus and its variants, therapeutics play a critical role in the COVID-19 response. They help to save lives, speed up recovery time, reduce the length of hospitalisation and ultimately ease the burden of health care systems.

Advertisement

The product from Eli Lilly is a combination of two monoclonal antibodies (bamlanivimab and etesevimab) for the treatment of coronavirus patients who do not require oxygen but are at high risk of severe COVID-19. Monoclonal antibodies are proteins conceived in the laboratory that mimic the immune system's ability to fight the coronavirus. They fuse to the spike protein and thus block the virus's attachment to the human cells.

Under the EU Joint Procurement Agreement, the European Commission has concluded until now nearly 200 contracts for different medical countermeasures with a cumulative value of over €12 billion. Under the joint procurement framework contract concluded with Eli Lilly, member states can purchase the combination product bamlanivimab and etesevimab if and when needed, once it has received either a conditional marketing authorisation at EU level from the European Medicines Agency or an emergency use authorisation in the member state concerned.

Background

Advertisement

Today's joint procurement contract follows the contract signed with Roche for the product REGN-COV2, a combination of Casirivimab and Imdevimab, on 31 March 2021 and the contract with Glaxo Smith Kline on 27 July 2021 for the supply of sotrovimab (VIR-7831), developed in collaboration with VIR biotechnology.

The EU Strategy on COVID-19 Therapeutics, adopted on 6 May 2021, aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. It will also coordinate, scale-up and ensure that the EU acts together in ensuring access to therapeutics via joint procurements.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. Focusing on the treatment of patients with COVID-19, the Strategy works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

On 29 June 2021, the strategy delivered its first outcome, with the announcement of five candidate therapeutics that could soon be available to treat patients across the EU. The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorization by October 2021, the target set under the strategy, provided the final data demonstrate their safety, quality and efficacy.

Global co-operation on therapeutics is crucial and a key component of our strategy. The Commission is committed to working together with international partners on COVID-19 therapeutics and make them available globally. The Commission is also exploring how to support the enabling environment for manufacturing health products, while strengthening research capacity in partner countries around the globe.

More information

EU Therapeutics Strategy

Coronavirus response

Safe COVID-19 vaccines for Europeans

Continue Reading
Advertisement
Advertisement
Advertisement

Trending